Targets › CXCL8
4 programs from 4 companies in 5 trials: 4 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.
Chemotactic factor that mediates inflammatory response by attracting neutrophils, basophils, and T-cells to clear pathogens and protect the host from infection. Also plays an important role in neutrophil activation. (UniProt, P10145)
Open in Phaseline: the race on CXCL8, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Adakitug (BMS-986253) Interleukin-8 inhibitor | CXCL8 | Phase 2 | Pancreatic Cancer; Head and Neck Squamous Cell Carcinoma | Dec 2026 |
| Icahn School of Medicine at Mount Sinai | Adakitug (BMS-986253) Interleukin-8 inhibitor | CXCL8 | Phase 2 | Non-small Cell Lung Cancer | Jul 2028 |
| The Netherlands Cancer Institute | Adakitug (BMS-986253) Interleukin-8 inhibitor | CXCL8 | Phase 2 | Colon Carcinoma | Mar 2032 |
| Yana Najjar | Adakitug (BMS-986253) Interleukin-8 inhibitor | CXCL8 | Phase 1 | Melanoma | Aug 2027 |
Non-small Cell Lung Cancer (1) Pancreatic Cancer (1) Head and Neck Squamous Cell Carcinoma (1) Colon Carcinoma (1) Melanoma (1)
mixed (4)
Icahn School of Medicine at Mount Sinai (1) Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) The Netherlands Cancer Institute (1) Yana Najjar (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.